What is Confo Therapeutics?
Confo Therapeutics operates as a clinical-stage biotechnology firm specializing in the discovery of novel medicines that target G-protein coupled receptors (GPCRs). By leveraging its proprietary discovery platform, the company identifies and develops both small molecules and antibodies with precise pharmacological profiles. This technological edge allows Confo to address unmet medical needs by unlocking the therapeutic potential of GPCRs, which are involved in a vast array of human diseases. The company's market position is defined by its ability to bridge the gap between structural biology and drug development, positioning it as a key innovator in the pharmaceutical industry.
How much funding has Confo Therapeutics raised?
Confo Therapeutics has raised a total of $98.4M across 2 funding rounds:
Series A
$33.4M
Series B
$65M
Series A (2019): $33.4M, investors not publicly disclosed
Series B (2024): $65M led by Driehaus Capital Management, Quest for Growth, and Ackermans & Van Haaren
Key Investors in Confo Therapeutics
Driehaus Capital Management
An investment management firm established in 1982, specializing in growth-oriented equity strategies and providing institutional-grade capital to high-potential enterprises.
Quest for Growth
A Belgium-based mutual fund that focuses on long-term value creation by investing in both listed and unlisted technology and life sciences companies across Europe.
Ackermans & Van Haaren
A diversified holding company with a long history of supporting growth capital initiatives across multiple sectors, including energy, real estate, and specialized healthcare.
What's next for Confo Therapeutics?
With the successful closure of its latest financing round, Confo Therapeutics is well-positioned to scale its clinical operations and expand its internal pipeline. The strategic focus will likely shift toward advancing lead programs into mid-stage clinical trials while simultaneously enhancing its discovery platform to identify new therapeutic targets. As the company matures, the integration of these capital resources will be instrumental in fostering potential partnerships with larger pharmaceutical entities, thereby validating its platform's scalability and long-term commercial viability in the competitive landscape of GPCR-targeted therapies.
See full Confo Therapeutics company page
